Title:An Overview of Adalimumab Therapy for Ankylosing Spondylitis
Volume: 20
Issue: 5
Author(s): Anna M. Sukhanova*, Mariam A. Gilavian, Elizaveta V. Melnik, Evgenia V. Shikh, Alexey E. Petukhov, Vladimir I. Gegechkori, Sergey P. Dementev, Alexander M. Vlasov and Galina V. Ramenskaya
Affiliation:
- Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical
University of the Ministry of Health of the Russian Federation (Sechenov University), 8-2 Trubetskaya Str., 119991
Moscow, Russia
- Moscow Research and Practical Centre on Addictions of Moscow, Department of Public Health,
37/1 Lyublinskaya Str., 109390 Moscow, Russia
Keywords:
Adalimumab, ankylosing spondylitis (AS), tumor necrosis factor (TNF), systematic review, efficacy, safety, randomized controlled trials.
Abstract:
Background: Ankylosing spondylitis (AS) is a chronic inflammatory disease known
for causing pain, stiffness, and reduced mobility in the axial skeleton. Adalimumab, a tumor necrosis
factor (TNF) inhibitor, has emerged as a promising therapeutic option for AS.
Methods: This systematic review involved a comprehensive search of randomized controlled
trials related to AS treatment, conducted in major databases such as MEDLINE, Google Scholar,
and PubMed. The search terms encompassed ankylosing spondylitis, adalimumab, methotrexate,
other non-biologic DMARDs, glucocorticoids, NSAIDs, and analgesics. A total of 14 randomized
controlled trials with 4,500 participants were included in the review.
Results: The review's results revealed that adalimumab demonstrated notable superiority when
compared to a placebo. It effectively reduced disease activity, improved physical function, and
lowered inflammatory markers such as C-reactive protein and erythrocyte sedimentation rate.
Adalimumab demonstrated a favorable safety profile, with adverse events comparable to those observed
with placebo.
Conclusion: Based on the results, adalimumab is deemed an effective treatment for AS, showcasing
its potential as a first-line therapeutic option. Notably, no significant increase in adverse
events was observed compared to placebo. However, the conclusion emphasizes the need for further
studies with extended follow-up durations to ascertain the long-term efficacy and safety of
adalimumab in AS management. This systematic review provides valuable insights supporting the
use of adalimumab in the treatment of AS and underscores the importance of ongoing investigations
into its long-term effects to optimize its clinical utilization in AS patients.
